NASDAQ:ARVN Arvinas Q3 2023 Earnings Report $6.61 -0.20 (-2.94%) As of 05/9/2025 04:00 PM Eastern Earnings HistoryForecast Arvinas EPS ResultsActual EPS-$1.18Consensus EPS -$1.58Beat/MissBeat by +$0.40One Year Ago EPS-$1.24Arvinas Revenue ResultsActual Revenue$34.60 millionExpected Revenue$39.58 millionBeat/MissMissed by -$4.98 millionYoY Revenue Growth+14.20%Arvinas Announcement DetailsQuarterQ3 2023Date11/7/2023TimeQ3 2023 Earnings ReleaseConference Call DateTuesday, November 7, 2023Conference Call Time7:00AM ETUpcoming EarningsArvinas' Q2 2025 earnings is scheduled for Tuesday, July 29, 2025, with a conference call scheduled on Friday, August 1, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Arvinas Earnings HeadlinesContrasting Arvinas (NASDAQ:ARVN) and Mustang Bio (NASDAQ:MBIO)May 9 at 1:53 AM | americanbankingnews.comTruist Financial Reiterates Hold Rating for Arvinas (NASDAQ:ARVN)May 7 at 2:09 AM | americanbankingnews.comTrump to redistribute trillions of dollars What’s most shocking about this list for me is stock #2. It’s primed to be the biggest beneficiary of the DOGE administration’s efforts to eradicate the filth and corruption plaguing our government. But the thing is… it’s actually not an Elon stock.May 10, 2025 | Porter & Company (Ad)BMO Capital Markets Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock PriceMay 7 at 2:09 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), Design Therapeutics (DSGN) and Arvinas Holding Company (ARVN)May 6, 2025 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. ...May 6, 2025 | gurufocus.comSee More Arvinas Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arvinas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arvinas and other key companies, straight to your email. Email Address About ArvinasArvinas (NASDAQ:ARVN), a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.View Arvinas ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming?DexCom Stock: Earnings Beat and New Market Access Drive Bull CaseDisney Stock Jumps on Earnings—Is the Magic Sustainable? Upcoming Earnings Petróleo Brasileiro S.A. - Petrobras (5/12/2025)Simon Property Group (5/12/2025)JD.com (5/13/2025)NU (5/13/2025)Sony Group (5/13/2025)SEA (5/13/2025)Cisco Systems (5/14/2025)Toyota Motor (5/14/2025)Copart (5/15/2025)NetEase (5/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
